Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00473434
Status:
COMPLETED
Last Update Posted:
2012-12-05
First Post:
2007-05-11
Brief Title:
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
Sponsor:
Janssen-Cilag Pty Ltd
Organization:
Janssen-Cilag Pty Ltd
Study Overview
Official Title:
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to evaluate the dose distribution effectiveness and safety in patients with schizophrenia who are switched from an oral atypical antipsychotic to Paliperidone ER In this study patients and physicians know the name and the dose of the study drug Newly diagnosed patients will also be included in the study In general the recommended Paliperidone ER dose will be 6 mg once daily however some patients may require a higher or lower initial dose in the recommended range of 3 to 12 mg once daily The dose can be adjusted any point during the study to a maximum dose of 12mgday Flexible dosing was chosen to best mimic actual clinical practiceThe safety assessments to be conducted throughout this study including the regular monitoring and recording of all Adverse Events and Serious Adverse Events
Detailed Description:
This trial is a non-randomised both patient and physician know the study drug single arm open label multicentre study which is aimed to evaluate the dose distribution efficacy and safety in patients with schizophrenia who are switched from an oral atypical antipsychotic to Paliperidone ER Newly diagnosed patients will also be included in the study In general the recommended Paliperidone ER dose will be 6 mg once daily however some patients may require a higher or lower initial dose in the recommended range of 3 to 12 mg once daily The dose can be adjusted any point during the study to a maximum dose of 12mgday Flexible dosing was chosen to best mimic actual clinical practiceThe study duration will be split into two phases Phase A will be 12 weeks and Phase B which will be an optional follow up phase will be 40 weeks Assessment of efficacy and safety will be performed in Phase A at baseline 2 4 6 9 and 12 weeks and in Phase B at 20 28 36 44 and 52 weeks At the first visit a full psychiatric history demographic data and physical examination will be undertaken Throughout the study the following procedures documentations and evaluations will be performed descriptions of concomitant medications hospitalisations for psychiatric reasons clinical deterioration Clinical Global Impression - Severity CGI-S and Global Assessment of Functioning GAF assessments Community Treatment Order CTO status weight adherence and adverse event reporting Physical examinations will be performed periodically Paliperidone ER OROS will be supplied in 3 mg 6 mg and 9 mg tablets for oral administration In general the recommended Paliperidone ER dose will be 6 mg once daily however some patients may require a higher or lower initial dose in the recommended range of 3 to 12 mg once daily The dose can be adjusted any point during the study to a maximum dose of 12mgday The study duration will be split into two phases Phase A will be 12 weeks and Phase B which will be an optional follow up phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R076477SCH3021 | None | None | None |